Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
about
Recent advances in understanding and managing cholestasisSystematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosisPrimary biliary cirrhosis: From bench to bedsidePrimary biliary cirrhosis: Pathophysiology, clinical presentation and therapyNuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?Clinical application of transcriptional activators of bile salt transporters.Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation.PPARα: A Master Regulator of Bilirubin HomeostasisFibrates and cholestasisThe Cholangiopathies.Advances in pharmacotherapy for primary biliary cirrhosis.Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing CholangitisNuclear receptors as drug targets in cholestatic liver diseases.Proposed therapies in primary biliary cholangitis.Upregulation of PDZK1 by Calculus Bovis Sativus May Play an Important Role in Restoring Biliary Transport Function in Intrahepatic Cholestasis.Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver.Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis.New therapies for primary biliary cirrhosis.New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition.It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology.Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate.Emerging drugs for the treatment of Primary Biliary Cholangitis.Management of cholestatic disease in 2017.Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review.Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.Primary biliary cholangitis: a comprehensive overview.From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.New therapeutics in primary biliary cirrhosis: will there ever be light?Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.Tissue distribution and ontogeny of multidrug resistance protein 2, a phosphatidylcholine translocator, in rats.Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic HCV Infection: A Possible Impact on the Efficacy and Safety of IFN-free Treatment.Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner.In vitro cytogenetic toxicity of bezafibrate in human peripheral blood lymphocytes.Investigational drugs in phase II clinical trials for primary biliary cholangitis.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3.Primary biliary cholangitis: new treatments for an old disease.Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.Guidelines for the management of primary biliary cirrhosis
P2860
Q26748537-F0944974-9C74-4DCE-A870-254795B557DAQ26778511-18A65985-147D-45AC-9E63-E102F8F215D0Q26799419-FD2823F8-E2A8-4E37-82B6-5B4633CFCB21Q26853649-F8FCED90-B2BC-4440-BFF5-7FB269985F44Q28066233-29E40B5A-B604-455E-A2DF-CD0AD18A6604Q33709930-B3B955C8-C6E7-4C02-8F99-7B5A7C6D2A04Q33721771-B324B019-406C-4E3B-BF2C-6E5DB08861F6Q34043010-30E63A55-E466-4F35-AD81-763A133713EEQ34053116-22BFA4AF-B46A-4CAA-A540-419BED8D0470Q35889448-31FA09EE-1B07-4226-A4F4-F20D3B829E3DQ35942610-9FF559FE-0D12-4816-BD19-90D3B7948142Q36116022-F82BF278-1D3F-42DE-86B7-58648FF07065Q36752084-E39C1183-7B59-4A9A-BEF7-41ED55A62ED4Q36786270-DCD5BB3E-47B5-4BA1-AF4A-F31BECA8DB77Q37072380-5FA1336C-AB56-412C-AB38-4F6951E744FAQ37590885-82DFDDA0-22B5-473A-99E6-3CF50696BB18Q38074991-7E568BF0-7760-48B5-903D-1914CDC0FD0AQ38174167-AC0BB2A7-0835-460E-B5C1-BEA5141ABFAEQ38261577-FDC9770A-9C22-434D-AB36-78CA3AB300BCQ38266172-D6452584-B295-4B4D-B81C-4D90532E2D3BQ38620686-E4015B85-CD26-4D0C-B302-6D3F92928E2CQ38711012-5038312E-07DC-4EE7-8DC7-1994165853D3Q38744215-F93FCDA9-7A9F-4EA6-A1CE-9CE71FC3E09FQ38774857-DB341FF2-4DC3-43A2-A8FC-D81C8AD3452CQ39314534-B04C63FA-E700-48C1-87E3-91379EC1D959Q42649890-365C99ED-0843-42C9-A32D-76752B0AB6F4Q46078221-F5437776-51FC-447F-B502-74F717C1ECFEQ46135644-5C6725D6-5381-4593-BE9F-838D6401F739Q46182874-428F932D-FBBB-4FF0-9400-CFDFC0D53AB7Q47615113-B2F544EE-608C-4CC9-AD0A-ED07F6EF7828Q48496557-4B432A6D-FFCB-4DCE-9999-0AB909254D95Q49567497-3FFF484B-D918-495B-9210-3DAF3D5668B2Q49650135-C0D523DD-B219-44F8-8775-989977A56C64Q52801689-A855CAB6-4884-4BAF-8815-E48E0D9E3988Q53098304-2FECEE6F-ACDA-4C3C-A138-20FCE98B6C68Q53591523-29432139-BFD5-457D-85E4-19AA2BBB1982Q53813239-82720129-4003-44A1-883A-B461CC6D4594Q54390436-B4FD2C67-33DE-4918-9270-C8E357527971Q55190939-88124F0A-1847-4247-A2A7-3B4948CC1E3CQ56429943-4EA677B6-D21C-4DAF-9FA8-8F7E086DCD72
P2860
Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.
@en
Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.
@nl
type
label
Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.
@en
Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.
@nl
prefLabel
Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.
@en
Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.
@nl
P2093
P2860
P356
P1433
P1476
Anticholestatic effects of bez ...... ted with ursodeoxycholic acid.
@en
P2093
Akira Honda
Hajime Takikawa
Junichi Iwamoto
Makoto Nakamuta
Michio Imawari
Tadashi Ikegami
Takeshi Hirayama
Teruo Miyazaki
Yasushi Matsuzaki
Yoshifumi Saito
P2860
P304
P356
10.1002/HEP.26018
P407
P577
2013-04-05T00:00:00Z